FcRn Inhibitors and Novel Options for Myasthenia Gravis
FcRn Inhibitors and Novel Options for Myasthenia Gravis
Muscular Dystrophy Canada (MDC) is pleased to present a webinar on the neonatal Fc receptor (FcRn) pathway for people with generalized Myasthenia Gravis (gMG). MDC is excited to have their webinar speaker discuss next generation treatments for Myasthenia Gravis and help us understand how these treatments work in the neuromuscular pathway.